The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | First analysis of VenDd +/- V for RRMM shows unprecedented reponse
Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, discusses the first analysis from M15-654 (NCT03314181), a phase I/II, non-randomized, multicenter study of venetoclax in combination with daratumumab and dexamethasone (VenDd), with or without bortezomib (V), in patients with relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
